Peer-Reviewed Publications

      Mass spectrometric analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in human lung

      Hölzle, D.; Schlöbe, D.; Tricker, A. R.; Richter, E.
      Published
      Jan 30, 2007
      DOI
      10.1016/j.tox.2007.01.016
      PMID
      17321028
      Link to publication
      Topic
      Summary

      An improved analytical method was developed for the analysis of 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB)-releasing DNA adducts in lung samples of patients undergoing surgery for lung cancer. HPB-releasing adducts can be formed by metabolic activation of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N′-nitrosonornicotine, and have been reported to play an important role in tobacco carcinogenesis. [2,2,3,3-D4]HPB (D4-HPB) was used as an internal standard, and HPB released by acid hydrolysis of DNA was determined by gas chromatography/mass spectrometry in the negative ion chemical ionisation mode. The method is sensitive with a limit of detection of 5.9 fmol HPB and a limit of quantification of 15.2 fmol HBP/mg DNA. The recovery of HPB was 82 ± 17% and the background response was 10.1 ± 1.8 fmol HPB/sample. The concentration of HPB-releasing lung DNA adducts was significantly higher (p < 0.0001) in 21 self-reported smokers compared to in 11 self-reported nonsmokers (404 ± 258 fmol versus 59 ± 56 fmol HPB/mg DNA, respectively). HPB-releasing hemoglobin adduct concentrations were only marginally higher in a subset of 12 smokers compared to in 7 nonsmokers (63 ± 53 fmol versus 42 ± 34 fmol HPB/g hemoglobin; p = 0.36). No correlation was found between HPB-releasing adducts in DNA and hemoglobin (p = 0.074).

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.